[{"id":"afaf9f09-288f-48be-befd-287bbb78babe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04734990","created_at":"2021-02-02T15:52:24.117Z","updated_at":"2024-07-02T16:35:04.640Z","phase":"Phase 1/2","brief_title":"Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04734990","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • NRAS • RUNX1 • ASXL1 • SETBP1","pipe":" | ","alterations":" TP53 mutation • NRAS mutation • ASXL1 mutation","tags":["TP53 • NRAS • RUNX1 • ASXL1 • SETBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NRAS mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • seclidemstat (SP2577)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/11/2025","primary_completion_date":" 09/11/2025","study_txt":" Completion: 09/11/2025","study_completion_date":" 09/11/2025","last_update_posted":"2024-05-09"},{"id":"a010e6ed-344f-428e-a888-60e487dd1787","acronym":"SALA-002-EW16","url":"https://clinicaltrials.gov/study/NCT03600649","created_at":"2021-04-14T16:53:42.104Z","updated_at":"2024-07-02T16:35:28.552Z","phase":"Phase 1","brief_title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","source_id_and_acronym":"NCT03600649 - SALA-002-EW16","lead_sponsor":"Salarius Pharmaceuticals, LLC","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • seclidemstat (SP2577)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-21"},{"id":"50472ebf-13f3-4a6d-abc3-8b39f9bfd5ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04611139","created_at":"2021-01-19T20:32:44.176Z","updated_at":"2025-02-25T16:10:47.159Z","phase":"Phase 1","brief_title":"Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers","source_id_and_acronym":"NCT04611139","lead_sponsor":"HonorHealth Research Institute","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • seclidemstat (SP2577)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-03-01"}]